Policy | August 16, 2021
India restricts export of Rapid Antigen Test Kits used to detect Covid 19
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Demand normalisation post the second wave contributed to the steady growth
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The drug is indicated for mild and transient episodes of heart block
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Subscribe To Our Newsletter & Stay Updated
